A new targeted cancer drug, DB-1310, is showing early signs of effectiveness in patients with advanced solid tumors that have not responded to standard treatments, particularly those with EGFR-mutant non-small cell lung cancer (NSCLC), according to results from an international clinical trial led by Dr. Aaron Lisberg at the UCLA Health Jonsson Comprehensive Cancer Center.